RZH
NTLA icon

Relyea Zuckerberg Hanson’s Intellia Therapeutics NTLA Stock Holding History

Relyea Zuckerberg Hanson’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,129
Closed -$229K – 265
2024
Q3 		$229K Buy
11,129
+176
+2% +$4.06K 0.03% 230
2024
Q2 		$245K Sell
10,953
-23
-0.2% -$548 0.04% 208
2024
Q1 		$302K Sell
10,976
-2,242
-17% -$62.3K 0.05% 181
2023
Q4 		$403K Buy
13,218
+2
+0% +$57 0.08% 132
2023
Q3 		$418K Sell
13,216
-97
-0.7% -$3.76K 0.1% 119
2023
Q2 		$543K Sell
13,313
-80
-0.6% -$3.24K 0.12% 105
2023
Q1 		$499K Buy
13,393
+20
+0.1% +$784 0.12% 101
2022
Q4 		$467K Buy
13,373
+149
+1% +$7.08K 0.13% 105
2022
Q3 		$740K Buy
13,224
+16
+0.1% +$993 0.27% 58
2022
Q2 		$684K Buy
13,208
+2
+0% +$102 0.25% 62
2022
Q1 		$832K Buy
+13,206
New +$1.12M 0.27% 60

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Relyea Zuckerberg Hanson's NTLA Position: Q4 2024 in Review

Relyea Zuckerberg Hanson sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 11,129 shares — an estimated $229K sold.

Relyea Zuckerberg Hanson first reported a position in NTLA in Q1 2022 and held it in 11 quarters. The position peaked at $832K in Q1 2022. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Relyea Zuckerberg Hanson reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Relyea Zuckerberg Hanson sold 11,129 Intellia Therapeutics shares in Q4 2024, an estimated $229K.
  • Relyea Zuckerberg Hanson first reported a position in Intellia Therapeutics in Q1 2022 and held it in 11 quarters.
  • Relyea Zuckerberg Hanson's Intellia Therapeutics position peaked at $832K in Q1 2022.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Relyea Zuckerberg Hanson's 13F filing for Q4 2024, filed 15 Jan 2025.